• Viral RIPK3 Degradation and Inflammation

  2026-09-22

  Liu and colleagues identified a cowpox virus protein class that redirects the host SCF ubiquitin machinery to degrade RIPK3, thereby suppressing necroptosis and reshaping viral inflammation. The study links this viral inhibitor to orthopoxvirus replication, disease severity, and pathogen–host evolution through complementary genetic, biochemical, and mouse infection experiments.

• RBMS1 Loss Rewires PD-L1 Stability in TNBC

  2026-09-22

  The reference study identifies RBMS1 as an RNA-binding protein that sustains PD-L1 expression in immune-cold triple-negative breast cancer by stabilizing B4GALT1 mRNA and preserving PD-L1 glycosylation. RBMS1 depletion reduced tumor-cell immune suppression and improved responses to checkpoint blockade and CAR-T treatment in experimental models, highlighting post-transcriptional control of PD-L1 as a potential combination-immunotherapy strategy.

• Novobiocin Workflows for Antimicrobial Research

  2026-09-21

  Novobiocin is an aminocoumarin antibiotic that supports bacterial, antiparasitic, antiviral, and Hsp90-focused research in one adaptable platform. This guide translates a validated microdilution and synergy framework into practical Novobiocin workflows, with concentration planning, assay controls, and troubleshooting for reproducible results.

• PP 2 (AG 1879): Src Kinase Workflow Guide

  2026-09-21

  PP 2 (AG 1879) combines strong Lck and Fyn inhibition with practical utility in cancer, immune-signaling, and vascular experiments. This guide connects product handling to the reference study’s ROS–L-type calcium channel model while emphasizing concentration control, orthogonal validation, and off-target interpretation.

• Phosphatase Inhibitor Cocktail for Glioma Signaling

  2026-09-20

  Protect phosphorylation-dependent readouts in glioma lysates, immunoprecipitation workflows, kinase assays, and phosphoproteomics. This guide translates a recent anoikis–PLAU study into practical sample-handling decisions while emphasizing sequential dual-tube use, assay compatibility, and troubleshooting.

• NAT10–ac4C Control of Mouse Oocyte Maturation

  2026-09-19

  The reference study identifies NAT10-mediated N4-acetylcytidine (ac4C) as a post-transcriptional regulator of mouse oocyte maturation in vitro. NAT10 knockdown reduced ac4C and delayed first polar body extrusion, while transcriptomic and RNA-pulldown analyses implicated chromatin-associated processes and TBL3 as a potential ac4C-binding protein.

• SR 11302: AP-1 Transcription Factor Inhibition

  2026-09-18

  SR 11302 is a selective AP-1 transcription factor inhibitor for separating AP-1-driven proliferation, tumor promotion, and immune signaling from retinoid receptor activity. This practical guide connects cancer-cell assays with macrophage-polarization workflows and provides formulation, control, and troubleshooting strategies for reproducible studies.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-09-18

  This 2024 study identifies a mechanistic route by which lithium enhances BMSC osteogenesis: MARK2-dependent Rab11a trafficking increases exosomal Wnt10a secretion, activating β-catenin signaling in recipient cells. Lithium-conditioned exosomes and GelMA delivery improved osteogenic outcomes in cellular and bone-repair models, providing a framework for engineered exosome therapies.

• Sulfo-Cy5 NHS Ester: Aqueous Protein Labeling

  2026-09-17

  Sulfo-Cy5 NHS ester is a sulfonated, amine-reactive fluorescent reagent for aqueous protein conjugation. Its reported 646 nm excitation maximum, 662 nm emission maximum, and high extinction coefficient support sensitive fluorescence imaging when labeling, cleanup, storage, and target controls are properly managed.

• Fenofibrate: Reliable Assay Design for Cell Studies

  2026-09-17

  This scenario-driven guide explains how Fenofibrate (SKU B1943) can support interpretable cell viability, proliferation, cytotoxicity, and PPARα–YAP experiments. It covers formulation, concentration planning, time-course design, data interpretation, and practical supplier-selection criteria.

• LIRP Enables Light-Controlled Gene Therapy

  2026-09-16

  A 2026 Trends in Biotechnology study describes a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. In mouse models, LIRP-regulated AAV systems enabled ambient-light activation for metabolic disease and reversible light-dependent interruption of retinal VEGF inhibition.

• Low-Cost Microfluidic Mixers for LNP Research

  2026-09-16

  The 2025 Pharmaceutics study evaluates two low-cost microfluidic mixers against pipette mixing for lipid nanoparticle manufacture. Its central finding is that inexpensive approaches can produce well-encapsulated LNPs and support useful high-throughput screening, although orthogonal characterization remains necessary because similar size and encapsulation values can conceal functional differences.

• HMGB1 Proteomics for Early Diabetic Nephropathy

  2026-09-15

  The iScience study integrates quantitative serum proteomics with Mfuzz clustering and WGCNA to identify proteins that track diabetic nephropathy progression, highlighting HMGB1 as a candidate early-monitoring biomarker. Its findings support a staged, multi-method strategy in which discovery proteomics is followed by orthogonal validation rather than immediate clinical adoption.

• Fasting, eIF4E Phosphorylation, and Tumor Metabolism

  2026-09-15

  The reference study identifies phosphorylation of eIF4E as a selective translational control mechanism that enables the liver to produce ketone bodies during fasting and ketogenic feeding, even while overall protein synthesis declines. Its findings connect fatty-acid sensing through the AMPK–MNK–eIF4E axis with pancreatic tumor adaptation and suggest a diet–drug strategy for testing tumors that depend on ketone metabolism.

• αKG–Carnitine Control of DNA Repair and PARP Response

  2026-09-14

  The reference study identifies an αKG–TMLHE–carnitine pathway that sustains histone acetylation and homologous recombination in otherwise HR-proficient cancer cells. Its findings connect metabolic state to resistance against Olaparib, cisplatin, and radiation, suggesting a route for inducing functional HR deficiency without relying exclusively on BRCA1 or BRCA2 mutations.

8092 records 1/540 page Next 12345 下5页 Last page